Tumor-associated antigen presented via major histocompatibility complex class I molecule on dendritic cell

This target refers to **tumor-associated antigens** (typically peptides derived from cancer cell proteins) that are processed and displayed on the surface of **dendritic cells** (DCs) in the context of **major histocompatibility complex (MHC) class I molecules**. Dendritic cells have the unique ability to acquire antigens from dead or dying tumor cells, process them, and present these antigens on MHC I molecules—a process called **cross-presentation**[2]. This activates **CD8+ T cells**, which are crucial for anti-tumor immunity. Cross-presentation of tumor-associated antigens on MHC I by DCs is central to effective cancer immunotherapies such as dendritic cell vaccines and influences responses to checkpoint blockade therapies[1][2][3][4]. Alterations in MHC I antigen presentation represent a major mechanism of tumor immune evasion and are critical in the design and monitoring of immunotherapy strategies[1]. Additional notes: - The query describes a **complex/functional unit**, not a single molecular entity. This is not a standard molecular target (e.g., receptor, enzyme) but a composite immunological structure comprising a peptide antigen, MHC I molecule, and dendritic cell context. - Entries such as this should likely be flagged as problematic for structured databases focused on canonical single targets, as the name is broad, lacks unique specificity, and encompasses both a ligand (antigen) and a presenting context (MHC I + DC)[1][2][3]. - MHC class I–presented tumor antigens on DCs are **indirect** drug targets; most therapies affect the process (antigen loading, DC activation, checkpoint inhibition) rather than the molecule itself. If you need a canonical form for a structured database, represent with: "Tumor-associated antigen presented via MHC class I molecule on dendritic cell" and set **is_incorrect** to true for clarity.

Other names

Tumor antigen-MHC I complex on dendritic cellTumor-associated peptide-MHC I complex on DCTumor-derived antigen cross-presented by dendritic cell MHC I

Enhancement of CD8+ T cell activation via improved antigen cross-presentation; Restoring or increasing MHC I antigen presentation on tumor cells or dendritic cells; Blocking immune checkpoints to boost T cell cytotoxicity against antigen-presenting cells